BioSpace News Archive

Annexon, Inc. today announced that Dean “Rick” Artis, Ph.D., has been appointed as chief scientific officer (CSO), succeeding Larry C. Mattheakis, Ph.D.

Microbot Medical Inc., the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, announced that Joe Mullings, a renowned and successful leader in the medtech space, will moderate the next Access-Ability Live by MBOT webinar.

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT04, Alvotech’s proposed biosimilar to Stelara®, which is prescribed to treat a variety of inflammatory conditions.

Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415.

Aurinia Pharmaceuticals Inc. provided an update on its business performance.

BD, a leading global medical technology company, announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023.

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine.

Aclaris Therapeutics, Inc. today is providing a corporate outlook for 2023.

Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 10, 2023 at 7:30 am (PT).

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million.